implantable-devices
(3)
Presidio Medical, Inc.
Presidio Medical is a clinical-stage medical device company in San Mateo, California, developing a proprietary Ultra Low Frequency (ULF) neuromodulation platform. By delivering very low frequency biphasic electrical currents through leads implanted in the epidural space, Presidio's spinal cord stimulation system reversibly blocks the conduction of pain signals along nerves without damaging tissue. Its first target is chronic nociceptive low back pain, a large and underserved indication with no approved SCS therapy. Backed by Deerfield Management and others, the company raised a $72M Series C in 2023 and received FDA IDE approval in 2025 to run its global pivotal FULFILL trial.
XII Medical
XII Medical is a Union City, California medical device company building a minimally invasive neuromodulation therapy for obstructive sleep apnea (OSA). Founded in 2017 and led by CEO Garrett Schwab, the company is developing an implantable platform designed to be smaller, more flexible and easier to implant than existing nerve-stimulation systems - an alternative for the estimated 425 million people worldwide with moderate-to-severe OSA who struggle with CPAP masks. Backed by Cleveland Clinic, Ajax Health, Omega Funds and Intuitive Ventures, XII Medical closed a $45M Series B in August 2024 to fund product and clinical development.
Adona Medical
Adona Medical is a clinical-stage medical device company in Los Gatos, California developing the Delphi System, a chronically adjustable interatrial shunt with integrated bi-atrial pressure monitoring designed to personalize heart failure therapy over time. A Shifamed portfolio company founded in 2019 by Brian Fahey, Amr Salahieh, and Lewis Schwartz, Adona uses shape memory nitinol and an external induction catheter to resize the shunt after implantation without further invasive procedures.